Clinical trials: in Finland
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
- Trial name
- POETYK SjS-1 (NCT05946941)
- Testing
- Deucravacitinib
- Where
- 199 sites in United States, Argentina and 31 more
- Volunteers
- 774 people
- Sponsor
- Bristol-Myers Squibb
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this…
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
- Trial name
- NCT06563804
- Testing
- S227928, Venetoclax
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 13 people
- Sponsor
- Servier Bio-Innovation LLC
Validation
Validity and Feasibility of Newborn Bed Monitoring Device - a Clinical Pilot Study
The aim of this clinical pilot study is to evaluate the validity, acceptability and usability of the newborn bed monitoring device among newborns, parents and healthcare professionals in hospital environment.
- Trial name
- NCT06679127
- Where
- Finland
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anna Axelin
HIV Infection
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency…
- Trial name
- NCT04223791
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Overriding Distal Metaphyseal Radius Fractures
Casting Versus Percutaneus Pinning Treatment of Pediatric Overriding Distal Forearm Fractures
This is a randomized controlled trial comparing casting in finger-trap traction without reduction versus closed reduction and percutaneous pin fixation of dorsally displaced, overriding distal metaphyseal radius fractures in…
- Trial name
- NCT04323410
- Testing
- Cast immobilization, Percutaneus pinning
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- Töölö Hospital
Multiple Myeloma
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation…
- Trial name
- NCT06932562
- Testing
- Linvoseltamab, Daratumumab, Lenalidomide
- Where
- 59 sites in Australia, Austria and 16 more
- Volunteers
- 1,000 people
- Sponsor
- European Myeloma Network B.V.
Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score.
- Trial name
- AirGOs-biol (NCT04823585)
- Testing
- Mepolizumab
- Where
- Finland
- Volunteers
- 95 people
- Sponsor
- Helsinki University Central Hospital
Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
- Trial name
- SHINE (NCT06425159)
- Testing
- BHV-7000
- Where
- 109 sites in United States, Australia and 12 more
- Volunteers
- 27 people
- Sponsor
- Biohaven Therapeutics Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT06003426
- Testing
- BMS-986278
- Where
- 390 sites in United States, Argentina and 31 more
- Volunteers
- 1,255 people
- Sponsor
- Bristol-Myers Squibb
Fabry Disease
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry…
- Trial name
- NCT03566017
- Testing
- pegunigalsidase alfa
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 97 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Adults, Plaque, Dental
Photodynamic Treatment in the Management of Residual Biofilm - a Crossover Study
This research introduces a home-use dual-light antibacterial medical device and its possible added value as part of traditional dental self-care.
- Trial name
- NCT06860321
- Testing
- Adjunct antibacterial home-use dual-light medical device, Regular oral self care
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Koite Health Oy
Carpal Tunnel Surgery, Median Nerve Compression
Efficacy of Proximal Median Nerve Release
A multi-center randomized controlled clinical trial which determines the efficacy of proximal median nerve release in patients with persistent proximal median nerve compression.
- Conditions
- Carpal Tunnel Surgery, Median Nerve Compression, Median Nerve Entrapment
- Trial name
- PROMER (NCT07484100)
- Testing
- Proximal median nerve release, Physiotherapy
- Where
- 2 sites in Finland
- Volunteers
- 160 people
- Sponsor
- Tampere University Hospital
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Advanced Breast Cancer
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
- Trial name
- VERITAC-2 (NCT05654623)
- Testing
- ARV-471, Fulvestrant
- Where
- 312 sites in United States, Argentina and 29 more
- Volunteers
- 624 people
- Sponsor
- Pfizer
Venous Ulcer
Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System
The purpose of this study is to investigate the functionality of a new type of wound monitoring method and measurement system for monitoring healing of venous ulcers.
- Trial name
- WoundWatch® (NCT05805137)
- Testing
- WoundWatch® wound monitoring system
- Where
- 2 sites in Finland, Poland
- Volunteers
- 20 people
- Sponsor
- CutoSense Oy
Respiratory Syncytial Virus Infections
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
The purpose of this follow-up study was to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study.
- Trial name
- NCT05705440
- Testing
- RSVPreF3 vaccine, Control
- Where
- 138 sites in United States, Argentina and 21 more
- Volunteers
- 3,855 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Scleroderma, Systemic
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis.
- Trial name
- VITALISScE™ (NCT05559580)
- Testing
- Avenciguat (BI 685509)
- Where
- 168 sites in United States, Argentina and 35 more
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the…
- Trial name
- NCT03590171
- Testing
- Bortezomib
- Where
- 15 sites in Australia, Austria and 13 more
- Volunteers
- 250 people
- Sponsor
- Charite University, Berlin, Germany
Patency of the Ductus Arteriosus, Acetaminophen
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth.
- Conditions
- Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
- Trial name
- TREOCAPA (NCT04459117)
- Testing
- Acetaminophen, NACL 0.9%
- Where
- 36 sites in Belgium, Denmark and 10 more
- Volunteers
- 804 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.